Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE(R) (glatiramer acetate injection) 40mg/mL

New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announced today that the U.S. Food and Drug Administrat... Biopharmaceuticals, Neurology, FDATeva Pharmaceutical, COPAXONE, Glatiramer, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news